AUS
NZ
UK
CA
USA
IND
Highlights
- Over 200 patients enrolled in vitiligo trial
- Study spans North America, Africa, and Europe
- Scenesse shows early repigmentation success
Clinuvel Pharmaceuticals (ASX:CUV) has achieved a key milestone by enrolling over 200 patients in its pivotal Phase III trial for Scenesse (afamelanotide 16mg), a systemic therapy aimed at treating vitiligo. This trial, known as CUV105, is being conducted across 37 international sites, with more than half of the participants based in the United States. Final patient screening is set to conclude this month, with initial results expected by late 2026.
Vitiligo, a chronic skin condition that leads to progressive loss of pigmentation, affects approximately 2% of the global population. The condition tends to have a more pronounced psychosocial and aesthetic impact on individuals with darker skin tones—an area of focus for this study. Clinuvel’s investigational therapy, Scenesse, aims to restore pigmentation throughout the body, offering a potential breakthrough where existing treatments remain limited.
The treatment protocol involves patients receiving Scenesse in combination with narrowband ultraviolet B (NB-UVB) phototherapy twice a week over a 20-week period, or NB-UVB alone. Those assigned to the monotherapy group will become eligible for combination therapy after completing the follow-up phase. The primary clinical endpoint will be measured using the Vitiligo Area Scoring Index (VASI), targeting at least 50% repigmentation across the body. Secondary outcomes will assess facial and head repigmentation, as well as sustained results post-treatment.
Encouraging results have already emerged from earlier case studies, where patients demonstrated visible repigmentation of vitiliginous lesions within just four weeks. In some cases, spontaneous repigmentation continued even after the treatment had ended. All participants in these case studies tolerated the therapy well and expressed satisfaction with their outcomes.
According to Clinuvel’s Director of Global Clinical Affairs, Dr Emilie Rodenburger, this milestone signals not only progress in the trial but also preparation for broader market distribution in North America. The company is simultaneously continuing regulatory discussions across the US, Europe, and Africa in preparation for a second major trial, CUV107.
This momentum is particularly noteworthy within the context of Australia's biotech sector, as Clinuvel is a constituent of the ASX300 index. Its progress adds to investor interest in healthcare stocks, especially those that show both growth potential and stability. For income-focused investors, it's worth noting the broader category of ASX dividend stocks, which can complement biotech holdings in a diversified portfolio.
As clinical data continues to evolve, Clinuvel’s developments in vitiligo therapy could position it as a key player in addressing a long-standing unmet medical need, while also reinforcing its standing among ASX 300 constituents.
